Sun Pharmaceutical Industries Ltd. on Wednesday said its specialty product Ilumetri has been included in category B of China's national reimbursement drug list.
Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The inclusion of Ilumetri (Tildrakizumab) in China's national reimbursement drug list will be officially implemented from Jan. 1, 2024, Sun Pharmaceutical Industries said in a regulatory filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
In June 2019, Sun Pharma had out-licensed Tildrakizumab to a subsidiary of China Medical System Holdings Ltd., for the Greater China market.
Ilumetri was approved for marketing in China in May 2023, it added.
"The inclusion of Ilumetri in category B of the national reimbursement drug list will further improve the accessibility and affordability of the innovative drug to benefit more patients," it added.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.